KalVista Pharmaceuticals Stock Price, News & Analysis (NASDAQ:KALV)

$9.85 0.10 (1.03 %)
(As of 12/13/2017 03:58 AM ET)
Previous Close$9.75
Today's Range$9.60 - $10.10
52-Week Range$5.48 - $15.80
Volume52,400 shs
Average Volume79,336 shs
Market Capitalization$97.91 million
P/E RatioN/A
Dividend YieldN/A
Beta2.82

About KalVista Pharmaceuticals (NASDAQ:KALV)

KalVista Pharmaceuticals logoKalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.

Receive KALV News and Ratings via Email

Sign-up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KALV
CUSIPN/A
Phone857-999-0075

Debt

Debt-to-Equity Ratio0.01%
Current Ratio7.88%
Quick Ratio7.88%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.50 million
Price / Sales63.76
Cash FlowN/A
Price / CashN/A
Book Value$3.22 per share
Price / Book3.06

Profitability

Trailing EPSN/A
Net Income$-18,600,000.00
Net Margins-4,191.47%
Return on Equity-60.42%
Return on Assets-55.11%

Miscellaneous

Employees28
Outstanding Shares9,710,000

KalVista Pharmaceuticals (NASDAQ:KALV) Frequently Asked Questions

What is KalVista Pharmaceuticals' stock symbol?

KalVista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

How were KalVista Pharmaceuticals' earnings last quarter?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) posted its quarterly earnings results on Thursday, September, 14th. The specialty pharmaceutical company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.08. The specialty pharmaceutical company had revenue of $0.10 million for the quarter. KalVista Pharmaceuticals had a negative net margin of 4,191.47% and a negative return on equity of 60.42%. View KalVista Pharmaceuticals' Earnings History.

Where is KalVista Pharmaceuticals' stock going? Where will KalVista Pharmaceuticals' stock price be in 2017?

1 equities research analysts have issued twelve-month target prices for KalVista Pharmaceuticals' shares. Their forecasts range from $27.00 to $27.00. On average, they anticipate KalVista Pharmaceuticals' stock price to reach $27.00 in the next year. View Analyst Ratings for KalVista Pharmaceuticals.

Who are some of KalVista Pharmaceuticals' key competitors?

Who are KalVista Pharmaceuticals' key executives?

KalVista Pharmaceuticals' management team includes the folowing people:

  • Richard Aldrich, Chairman of the Board (Age 63)
  • Thomas Andrew Crockett, Chief Executive Officer, Director (Age 42)
  • Benjamin L. Palleiko, Chief Financial Officer (Age 51)
  • Christopher Yea Ph.D., Chief Development Officer (Age 53)
  • Arnold L. Oronsky Ph.D., Director (Age 77)
  • Joshua Resnick M.D., Director (Age 42)
  • Rajeev Shah, Director (Age 40)
  • Albert Cha M.D. Ph.D., Independent Director (Age 45)
  • Edward W. Unkart CPA, Independent Director (Age 67)

How do I buy KalVista Pharmaceuticals stock?

Shares of KalVista Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is KalVista Pharmaceuticals' stock price today?

One share of KalVista Pharmaceuticals stock can currently be purchased for approximately $9.85.

How big of a company is KalVista Pharmaceuticals?

KalVista Pharmaceuticals has a market capitalization of $97.91 million and generates $1.50 million in revenue each year. KalVista Pharmaceuticals employs 28 workers across the globe.

How can I contact KalVista Pharmaceuticals?

KalVista Pharmaceuticals' mailing address is ONE KENDALL SQUARE BUILDING 200 STE. 2203, CAMBRIDGE MA, 02139. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]


MarketBeat Community Rating for KalVista Pharmaceuticals (KALV)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  96 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  165
MarketBeat's community ratings are surveys of what our community members think about KalVista Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

KalVista Pharmaceuticals (NASDAQ:KALV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.502.50
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $27.00$27.00$18.00$7.95
Price Target Upside: 177.21% upside177.21% upside173.14% upside1,151.77% upside

KalVista Pharmaceuticals (NASDAQ:KALV) Consensus Price Target History

Price Target History for KalVista Pharmaceuticals (NASDAQ:KALV)

KalVista Pharmaceuticals (NASDAQ:KALV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017BTIG ResearchBoost Price TargetBuy$18.00 -> $27.00N/AView Rating Details
4/18/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$9.00 -> $8.00N/AView Rating Details
2/29/2016WedbushReiterated RatingOutperform$14.00N/AView Rating Details
2/2/2016Leerink SwannDowngradeOutperform -> Market Perform$15.00 -> $1.80N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

KalVista Pharmaceuticals (NASDAQ:KALV) Earnings History and Estimates Chart

Earnings by Quarter for KalVista Pharmaceuticals (NASDAQ:KALV)

KalVista Pharmaceuticals (NASDAQ KALV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/14/2017Q1 2018($0.59)($0.51)$0.10 millionViewN/AView Earnings Details
7/27/2017Q4 2017($0.43)$0.11 millionViewN/AView Earnings Details
11/8/2016Q3 2016($0.21)($0.09)$0.01 millionViewN/AView Earnings Details
11/11/2015Q315($0.26)($0.19)$0.01 million$0.01 millionViewListenView Earnings Details
8/11/2015Q215($0.21)($0.37)$0.01 million$0.01 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

KalVista Pharmaceuticals (NASDAQ:KALV) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for KalVista Pharmaceuticals (NASDAQ:KALV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

KalVista Pharmaceuticals (NASDAQ KALV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 49.10%
Institutional Ownership Percentage: 76.14%
Insider Trades by Quarter for KalVista Pharmaceuticals (NASDAQ:KALV)
Insider Trades by Quarter for KalVista Pharmaceuticals (NASDAQ:KALV)

KalVista Pharmaceuticals (NASDAQ KALV) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/12/2017Holdings A/S NovoMajor ShareholderSell2,725,283$9.64$26,271,728.12View SEC Filing  
10/12/2017Rajeev M ShahDirectorBuy850,000$8.50$7,225,000.00View SEC Filing  
9/15/2017Holdings A/S NovoMajor ShareholderSell176,647$7.21$1,273,624.87View SEC Filing  
9/14/2017Holdings A/S NovoMajor ShareholderSell10,000$8.05$80,500.00View SEC Filing  
9/13/2017Holdings A/S NovoMajor ShareholderSell25,900$8.02$207,718.00View SEC Filing  
12/30/2015David RenziCEOSell10,000$3.70$37,000.00View SEC Filing  
4/14/2015Acmp Iv LlcMajor ShareholderBuy877,500$5.00$4,387,500.00View SEC Filing  
4/14/2015Albert ChaDirectorBuy1,012,500$5.00$5,062,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

KalVista Pharmaceuticals (NASDAQ KALV) News Headlines

Source:
DateHeadline
KalVista Pharmaceuticals (KALV) & Its Peers Financial SurveyKalVista Pharmaceuticals (KALV) & Its Peers Financial Survey
www.americanbankingnews.com - December 11 at 11:22 PM
Head to Head Survey: KalVista Pharmaceuticals (KALV) vs. Its PeersHead to Head Survey: KalVista Pharmaceuticals (KALV) vs. Its Peers
www.americanbankingnews.com - December 8 at 7:46 PM
KalVista Pharmaceuticals to Present at Stifel Healthcare Conference - Business Wire (press release)KalVista Pharmaceuticals to Present at Stifel Healthcare Conference - Business Wire (press release)
www.businesswire.com - November 8 at 11:19 AM
KalVista Pharmaceuticals to Present at Stifel Healthcare ConferenceKalVista Pharmaceuticals to Present at Stifel Healthcare Conference
finance.yahoo.com - November 8 at 11:19 AM
KalVista Pharmaceuticals (KALV) vs. Sinovac Biotech (SVA) Head-To-Head ReviewKalVista Pharmaceuticals (KALV) vs. Sinovac Biotech (SVA) Head-To-Head Review
www.americanbankingnews.com - October 30 at 9:22 PM
BRIEF-Longwood Fund II reports 8.7 pct stake in Kalvista Pharmaceuticals ‍BRIEF-Longwood Fund II reports 8.7 pct stake in Kalvista Pharmaceuticals ‍
www.reuters.com - October 21 at 7:09 PM
KalVista Pharmaceuticals Inc (KALV): Time For A Financial Health CheckKalVista Pharmaceuticals Inc (KALV): Time For A Financial Health Check
finance.yahoo.com - October 21 at 7:09 PM
KalVista, Notable Investment and Collaboration AgreementKalVista, Notable Investment and Collaboration Agreement
finance.yahoo.com - October 18 at 5:57 AM
Insider Buying: KalVista Pharmaceuticals, Inc. (KALV) Director Buys 850,000 Shares of StockInsider Buying: KalVista Pharmaceuticals, Inc. (KALV) Director Buys 850,000 Shares of Stock
www.americanbankingnews.com - October 16 at 7:22 PM
KalVista Pharmaceuticals, Inc. (KALV) Given New $27.00 Price Target at BTIG ResearchKalVista Pharmaceuticals, Inc. (KALV) Given New $27.00 Price Target at BTIG Research
www.americanbankingnews.com - October 16 at 10:08 AM
Holdings A/S Novo Sells 2,725,283 Shares of KalVista Pharmaceuticals, Inc. (KALV) StockHoldings A/S Novo Sells 2,725,283 Shares of KalVista Pharmaceuticals, Inc. (KALV) Stock
www.americanbankingnews.com - October 12 at 10:20 PM
Merck Acquires 9.9% Stake In KalVistaMerck Acquires 9.9% Stake In KalVista
www.rttnews.com - October 12 at 3:02 AM
Todays Research Reports on Stocks to Watch: KalVista Pharmaceuticals and Nutanix Inc.Today's Research Reports on Stocks to Watch: KalVista Pharmaceuticals and Nutanix Inc.
finance.yahoo.com - October 11 at 5:00 PM
Company News For Oct 11, 2017Company News For Oct 11, 2017
finance.yahoo.com - October 11 at 5:00 PM
ETFs with exposure to KalVista Pharmaceuticals, Inc. : October 11, 2017ETFs with exposure to KalVista Pharmaceuticals, Inc. : October 11, 2017
finance.yahoo.com - October 11 at 5:00 PM
KalVista Pharmaceuticals (KALV) Reports Collaboration with Merck (MRK) on Continuing Development of KVD001KalVista Pharmaceuticals (KALV) Reports Collaboration with Merck (MRK) on Continuing Development of KVD001
www.streetinsider.com - October 11 at 5:40 AM
KalVista Pharmaceuticals Inc. (KALV) Is Surging On Merck CollaborationKalVista Pharmaceuticals Inc. (KALV) Is Surging On Merck Collaboration
www.nasdaq.com - October 11 at 5:40 AM
BRIEF-Kalvista Pharmaceuticals announces collaboration with MerckBRIEF-Kalvista Pharmaceuticals announces collaboration with Merck
www.reuters.com - October 11 at 5:40 AM
Analyzing KalVista Pharmaceuticals (KALV) and Peregrine Pharmaceuticals (PPHM)Analyzing KalVista Pharmaceuticals (KALV) and Peregrine Pharmaceuticals (PPHM)
www.americanbankingnews.com - October 10 at 10:20 PM
KalVista Pharmaceuticals Announces Collaboration with MerckKalVista Pharmaceuticals Announces Collaboration with Merck
finance.yahoo.com - October 10 at 7:35 PM
UPDATE: KalVista shares surge 111% on news of Merck ownership stake, collaborationUPDATE: KalVista shares surge 111% on news of Merck ownership stake, collaboration
finance.yahoo.com - October 10 at 7:35 PM
KalVista Pharma Wins Big on Merck CollaborationKalVista Pharma Wins Big on Merck Collaboration
finance.yahoo.com - October 10 at 7:35 PM
KalVista Shares Skyrocket On Merck Collaboration, Ovid Pops -- Biotech MoversKalVista Shares Skyrocket On Merck Collaboration, Ovid Pops -- Biotech Movers
finance.yahoo.com - October 10 at 7:35 PM
​Merck takes stake in small Cambridge rare disease biotech, lifting shares​Merck takes stake in small Cambridge rare disease biotech, lifting shares
finance.yahoo.com - October 10 at 7:34 PM
Small-Cap Biotech Rockets After Dow's Merck Buys 10% StakeSmall-Cap Biotech Rockets After Dow's Merck Buys 10% Stake
finance.yahoo.com - October 10 at 7:34 PM
Should You Buy KalVista Pharmaceuticals Inc (KALV) For This Reason?Should You Buy KalVista Pharmaceuticals Inc (KALV) For This Reason?
finance.yahoo.com - October 5 at 5:59 AM
Financial Analysis: Kadmon Holdings (KDMN) versus KalVista Pharmaceuticals (KALV)Financial Analysis: Kadmon Holdings (KDMN) versus KalVista Pharmaceuticals (KALV)
www.americanbankingnews.com - September 28 at 10:20 AM
ETFs with exposure to KalVista Pharmaceuticals, Inc. : September 19, 2017ETFs with exposure to KalVista Pharmaceuticals, Inc. : September 19, 2017
finance.yahoo.com - September 19 at 9:59 PM
KalVista Pharmaceuticals (KALV) and Cardiome Pharma Corporation (CRME) Financial SurveyKalVista Pharmaceuticals (KALV) and Cardiome Pharma Corporation (CRME) Financial Survey
www.americanbankingnews.com - September 18 at 10:30 PM
KalVista Pharmaceuticals, Inc. :KALV-US: Earnings Analysis: Q1, 2018 By the Numbers : September 18, 2017KalVista Pharmaceuticals, Inc. :KALV-US: Earnings Analysis: Q1, 2018 By the Numbers : September 18, 2017
finance.yahoo.com - September 18 at 7:43 PM
Holdings A/S Novo Sells 10,000 Shares of KalVista Pharmaceuticals, Inc. (KALV) StockHoldings A/S Novo Sells 10,000 Shares of KalVista Pharmaceuticals, Inc. (KALV) Stock
www.americanbankingnews.com - September 15 at 10:46 PM
KalVista Pharmaceuticals, Inc. (KALV) Major Shareholder Holdings A/S Novo Sells 25,900 SharesKalVista Pharmaceuticals, Inc. (KALV) Major Shareholder Holdings A/S Novo Sells 25,900 Shares
www.americanbankingnews.com - September 15 at 10:46 PM
Insider Selling: KalVista Pharmaceuticals, Inc. (KALV) Major Shareholder Sells 176,647 Shares of StockInsider Selling: KalVista Pharmaceuticals, Inc. (KALV) Major Shareholder Sells 176,647 Shares of Stock
www.americanbankingnews.com - September 15 at 10:46 PM
KalVista Pharmaceuticals, Inc. (KALV) Issues Quarterly  Earnings Results, Beats Estimates By $0.08 EPSKalVista Pharmaceuticals, Inc. (KALV) Issues Quarterly Earnings Results, Beats Estimates By $0.08 EPS
www.americanbankingnews.com - September 15 at 10:36 AM
KalVista Pharmaceuticals Reports Fiscal First Quarter ResultsKalVista Pharmaceuticals Reports Fiscal First Quarter Results
finance.yahoo.com - September 15 at 3:16 AM
Head-To-Head Analysis: Kalvista Pharmaceuticals (KALV) and Biogen (BIIB)Head-To-Head Analysis: Kalvista Pharmaceuticals (KALV) and Biogen (BIIB)
www.americanbankingnews.com - September 7 at 2:28 AM
KalVista Pharmaceuticals, Inc. (KALV) Coverage Initiated by Analysts at BTIG ResearchKalVista Pharmaceuticals, Inc. (KALV) Coverage Initiated by Analysts at BTIG Research
www.americanbankingnews.com - August 31 at 7:46 AM
KalVista Pharmaceuticals to Present at Wedbush PacGrow Healthcare ConferenceKalVista Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 8 at 7:52 PM
Mirna Therapeutics (MIRN) and KalVista Pharmaceuticals (KALV) Critical AnalysisMirna Therapeutics (MIRN) and KalVista Pharmaceuticals (KALV) Critical Analysis
www.americanbankingnews.com - August 7 at 8:54 AM
KalVista Pharmaceuticals, Inc. :KALV-US: Earnings Analysis: Q4, 2017 By the Numbers : August 1, 2017KalVista Pharmaceuticals, Inc. :KALV-US: Earnings Analysis: Q4, 2017 By the Numbers : August 1, 2017
finance.yahoo.com - August 2 at 2:27 AM
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Announces  Earnings ResultsKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Announces Earnings Results
www.americanbankingnews.com - July 28 at 10:30 PM
KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Fourth Quarter and Full Year Financial ResultsKalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Fourth Quarter and Full Year Financial Results
finance.yahoo.com - July 28 at 12:59 AM
Comparing KalVista Pharmaceuticals (NASDAQ:KALV) & Syros Pharmaceuticals (SYRS)Comparing KalVista Pharmaceuticals (NASDAQ:KALV) & Syros Pharmaceuticals (SYRS)
www.americanbankingnews.com - July 22 at 12:13 PM
BRIEF-Kalvista Pharmaceuticals files for mixed shelf of upto $100 mlnBRIEF-Kalvista Pharmaceuticals files for mixed shelf of upto $100 mln
www.reuters.com - March 29 at 6:40 PM
KALVISTA PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersKALVISTA PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - March 27 at 5:40 PM
KALVISTA PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementKALVISTA PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
biz.yahoo.com - March 17 at 9:19 AM
KalVista Pharmaceuticals Reports Fiscal Third Quarter ResultsKalVista Pharmaceuticals Reports Fiscal Third Quarter Results
globenewswire.com - March 16 at 6:54 PM
KALVISTA PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportKALVISTA PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - March 16 at 6:54 PM
Form 3 KalVista Pharmaceuticals For: Mar 07 Filed by: Maetzel Andreas - StreetInsider.comForm 3 KalVista Pharmaceuticals For: Mar 07 Filed by: Maetzel Andreas - StreetInsider.com
www.streetinsider.com - March 11 at 12:19 AM
KalVista Pharmaceuticals Appoints Dr. Andreas Maetzel Senior Vice President of Medical - NasdaqKalVista Pharmaceuticals Appoints Dr. Andreas Maetzel Senior Vice President of Medical - Nasdaq
www.nasdaq.com - March 11 at 12:19 AM

SEC Filings

KalVista Pharmaceuticals (NASDAQ:KALV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

KalVista Pharmaceuticals (NASDAQ:KALV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

KalVista Pharmaceuticals (NASDAQ KALV) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.